4月29日，南京新百（600682）发布2024年年度报告，公司报告期内实现营业收入67.00亿元，同比上涨 1.98%，归属于上市公司股东的净利润2.30亿元。公司同时发布的2025年一季报显示，1—3月实现营收 15.69亿元，归属于上市公司股东的净利润1.29亿元。南京新百大健康业务仍占主导地位，2024全年持续 稳健增长，并披露了2024年度ESG报告，坚持可持续高质量发展。 生物医疗方面，2024年，齐鲁干细胞继续实施多元化发展策略，在现有的脐血干细胞保存服务基础上持 续创新推出多室保存服务，以及包括免疫细胞储存和检测在内的多样化产品与服务；公司全资子公司济 南科阅医学检验实验室有限公司开展健康与衰老评估、AD检测等项目，并在深圳设立了深圳卓元干细 胞工程有限公司，扩大业务范围。2024年，齐鲁干细胞全力推进国际细胞治疗认证基金会FACT认证， 并已于2025年2月成为国内首家获得FACT国际认证的细胞机构。这一里程碑标志着齐鲁干细胞的技术实 力与质量管理体系跻身全球领先行列，也意味着我国细胞治疗领域迈入国际标准化新阶段。 2024年，丹瑞美国不断强化PROVENGE作为早期无症状或轻微症状的mCR ...

金仕生物 全球首款预装干瓣Prostyle A® 获批上市 4月9日，金仕生物宣布由公司自主研发的 Prostyle A®经导管人工主动脉瓣膜置换系统-干法预装可回收输送 系统 获得国家药品监督管理局 （NMPA） 批准上市 （ 国械注准20253130729） 。 作为全球首款预装干瓣，金仕生物推出的新一代介入主动脉瓣Prostyle A®集成了众多瓣膜领域的前沿技 术，拥有干瓣技术、巧妙便捷的预装系统、卓越的瓣膜血流动力学性能和耐久性，优秀的输送性和通过 性，平稳的释放和可靠的锚定等特点。金仕生物自主创新的干瓣技术，在国内、欧洲、美国、日本等国家 享有专利保护。这一产品的出现，迎来中国TAVR的新时代 ——干瓣时代。 艾柯医疗 全新血流导向密网支架系统"Lattice COUPLE"成功获批 近日，艾柯医疗全新血流导向密网支架系统"Lattice COUPLE"，成功获得国家药监局批准注册 （ 注册证编 号：国械注准20253130668） 。至此， 艾柯医疗成为神经介入行业首家拥有三张密网注册证的企业 。 微光医疗 FDA 首次批准中国高端腔内介入影像设备 4月11日，微光医疗宣布其两款冠脉OCT设备及 ...

Core Viewpoint - Northeast Pharmaceutical's integration of "raw materials + formulations" establishes a solid foundation for sustainable development and enhances its competitiveness in the pharmaceutical market [1] Group 1: Innovation and R&D - The company is a significant drug production and export base in China, continuously increasing its investment in new product development, with a projected 7.55% growth in R&D investment for 2024 [2] - Northeast Pharmaceutical has formed a collaborative R&D network across Shenyang, Beijing, and Shanghai, improving R&D efficiency and accelerating the market launch of new products [2][3] - The company has approved the production of 5 generic drugs and has 6 innovative drugs entering clinical research in 2024, with a focus on cell therapy following the acquisition of a 70% stake in Dingcheng Peptide Source [2][3] Group 2: AI and Management Efficiency - The company has initiated a deep application of artificial intelligence (AI) to enhance management efficiency, identifying optimization points in production and reducing energy costs by 30,000 yuan per month on one production line [4][5] - AI applications have improved market response speed and operational quality, contributing to the company's transformation into an innovative international pharmaceutical group [5] Group 3: Market Position and Product Structure - Northeast Pharmaceutical has developed a comprehensive product structure covering ten major categories, including vitamins, anti-infectives, and oncology treatments, while optimizing its marketing system [6] - The company aims to meet the increasing public demand for quality and new drugs by leveraging its integrated advantages in raw materials and formulations, while actively entering the biopharmaceutical sector [6][7] Group 4: Cell Therapy Development - The acquisition of Dingcheng Peptide Source allows Northeast Pharmaceutical to develop a range of cell therapy products targeting various cancers, with a focus on TCR-T cell products [7] - The company plans to accelerate the development of its biopharmaceutical pipeline, aiming for significant progress in 2024 [7]

Group 1 - The second Shaanxi Province Cell Industry Innovation Conference was held in Xi'an, focusing on "Focusing on Cell Frontiers, Building a New Industry Journey" and officially unveiled the Shaanxi International Cell Gene Industry Transformation Base [1] - The conference attracted over 10 academicians, nearly 50 industry chain enterprises, and more than 1500 participants, highlighting the growing interest and investment in the cell industry [1] - Four core platforms were launched at the conference, including the National Stem Cell Transformation Resource Library (Northwest Branch) and the Shaanxi Province Cell Drug Innovation Center (in preparation), aiming to create an integrated ecosystem from basic research to clinical transformation and industrial application [1] Group 2 - Shaanxi has gathered over 100 biopharmaceutical companies, forming a complete chain covering storage, research and development, and production [2] - The China Western Innovation Port aims to deepen industry-university-research collaboration and promote the upgrade of the cell industry towards intelligent manufacturing [2] - Shaanxi Province aims to cultivate a trillion-level industrial cluster, striving to become a national innovation source for the cell industry [2]

Core Viewpoint - San Yuan Gene reported a revenue of approximately 257 million yuan for 2024, marking a year-on-year growth of 4.83%, alongside a significant increase in net cash flow from operating activities by 63.23% [2] Group 1: Financial Performance - The company achieved a revenue of approximately 257 million yuan in 2024, reflecting a year-on-year growth of 4.83% [2] - The net cash flow from operating activities increased by 63.23% compared to the previous year [2] Group 2: Research and Development - R&D expenses increased by 8.49 million yuan, a growth of 64.90%, primarily due to advancements in clinical trials for new PEG-integrated interferon mutant injection and γδT cell tumor immunotherapy [2] - The company has established five major technology platforms to support continuous innovation, including platforms for recombinant protein drug expression, high stability solutions, long-acting interferon preparation, inhalation formulations, and universal immune cell therapy [3] Group 3: Clinical Research and Development - The company is actively advancing the development of γδT cell tumor immunotherapy, aiming to create cost-effective "off-the-shelf" cell therapy products for broader clinical applications [4] - Clinical studies have been initiated for γδT cell therapy in various cancers, including melanoma and acute myeloid leukemia, with positive safety results reported [5] - A collaboration with Beijing Jiade and a leading γδT cell therapy team has been established to develop an international tumor immunotherapy platform [5][6] Group 4: Market Expansion - An expert consensus on the use of human interferon α1b for melanoma treatment was published, providing a solid foundation for expanding the company's market in tumor treatment [7]

Core Viewpoint - The company is focusing on innovation and market expansion in response to the evolving healthcare landscape, particularly in the fields of biomaterials, pharmaceuticals, and cell therapy, while ensuring sustainable development and internal governance optimization [2][6]. Company Overview - The company is actively engaged in the development of innovative products and technologies with independent intellectual property rights, aiming to enhance product quality and optimize product structure as core drivers of growth [2]. - The company has established a leading technology platform for animal-derived medical biomaterials, participating in over twenty national and local scientific projects [3]. Business Segments Biomaterials - The company has developed a series of regenerative medical materials that exhibit good tissue compatibility and promote tissue growth, with several products already on the market for various medical applications [3][4]. - Key products include biological dura (spinal) patches and sterile biological dressings, which are applicable in neurosurgery, thoracic surgery, dermatology, orthopedics, and more [4]. Pharmaceuticals - The company’s pharmaceutical research has yielded Baimuode, a first-in-class drug for treating inflammatory and autoimmune diseases, which has been included in the national medical insurance directory [4]. - Baimuode has potential applications in several important disease areas, with ongoing clinical trials for atopic dermatitis [4]. Cell Therapy - The company is enhancing its capabilities in the preparation of immune and stem cells, focusing on clinical efficacy and safety evaluations [5]. - Current projects include autologous cartilage cell transplantation and immune cell storage technology, aimed at treating joint cartilage defects and cancer, respectively [5]. Financial Data - The company has not required retrospective adjustments or restatements of previous financial data, indicating stable financial reporting practices [7]. - There are no significant discrepancies between the reported financial indicators and previously disclosed quarterly or semi-annual reports [7]. Future Outlook - The company plans to continue focusing on its three core business areas while enhancing innovation and market development efforts to navigate internal and external challenges [6].

Core Viewpoint - The company reported a slight decline in revenue and profit for 2024 but showed signs of recovery in Q1 2025, indicating improved operational conditions. Financial Performance - In 2024, the company achieved an operating revenue of 377 million yuan and a net profit attributable to shareholders of 27.42 million yuan, reflecting a year-on-year decline [1] - In Q1 2025, the company’s operating revenue increased by 3.67% year-on-year to 94.80 million yuan, with a net profit growth of 3.30% to 14.87 million yuan, indicating a recovery [1] Business Segments - The company operates in three main business segments: biomaterials, pharmaceuticals, and cell therapy, with a focus on high-value consumables and innovative medical devices [1] - The medical device segment's revenue remained stable, with a notable 21.52% increase in revenue from B-type dura (spinal) patches, reaching 72.14 million yuan [2] Pharmaceutical Developments - The company’s 1.1 class new drug, Benvimod cream, is recognized as a potential blockbuster, effective for inflammatory and autoimmune diseases, and is included in multiple treatment guidelines [2] - Benvimod has broad application prospects beyond psoriasis, including atopic dermatitis and ulcerative colitis, with ongoing Phase III clinical trials for atopic dermatitis [2] Cell Therapy Initiatives - The company is enhancing its capabilities in immune and stem cell preparation technologies, clinical efficacy, and safety assessments, with a focus on regulatory compliance [3] - Revenue from cell technology services has exceeded 10%, with expectations for further growth as the regulatory environment improves [3] Research and Development - The company is advancing its bioartificial liver project, focusing on the pharmaceutical research of cell drugs and the performance study of related medical devices [4] - Collaborations with hospitals for preclinical research are underway, which could lead to significant growth opportunities if successful [4]

Financing Overview - A total of 11 financing events occurred in Shanghai this week, with 6 disclosing amounts totaling approximately 390 million yuan [3][7] - The highest number of financing events took place in Songjiang District with 3 occurrences, followed by Pudong New District with 2 [3] Company Financing Dynamics - NeuShen Therapeutics completed a multi-million dollar Series A financing on April 18, led by Shanghai Biomedical Fund, with existing shareholders also participating. The funds will be used to advance clinical development of its core product NS-041 [13][14] - QiSeLian Biotechnology announced the completion of its angel round financing on April 17, focusing on personalized cell therapy and anti-aging technology [15][16] - WeiTi Robotics secured nearly 100 million yuan in angel and angel+ round financing on April 15, with investments from various venture capital firms. The funds will support the development of its bionic perception systems [17][18] - FuKe New Materials completed a Pre-A round financing of several tens of millions on April 15, aimed at enhancing its eco-friendly waterproof and oil-proof agents [19][20] - YiRen Technology completed a Pre-A round financing of several tens of millions on April 19, focusing on spatiotemporal intelligent data services [22][24] - DeYin Technology announced the completion of several tens of millions in angel round financing on April 18, aimed at expanding its elderly care robot product line [25][26] - JuErDa Technology secured 12 million yuan in angel round financing on April 17, focusing on cybersecurity solutions [27][28] - LiangWei Technology completed an angel+ round financing on April 14, focusing on interface-free material development [29][30] - JinZe Biotechnology completed a Pre-A round financing on April 14, focusing on intelligent detection and intervention products for cognitive disorders [31][32] - YunShen Technology completed an A round financing on April 14, focusing on semiconductor materials and equipment [33][34] - ShangGuang Communication completed an A+ round financing on April 15, focusing on laser communication technology [35][36] Industry Focus - The medical health sector saw 3 financing events this week, focusing on cell therapy, chemical preparations, and in vitro diagnostics [10][37] - The release of the first "White Paper on the Survival Status of Small Cell Lung Cancer Patients in China" highlights challenges in clinical diagnosis and patient survival [37] - Recent government policies are fostering high-quality development in the pharmaceutical industry, with a focus on innovative drugs and cell therapy, particularly in Shanghai, which has become a leader in this field [38]

Core Insights - The company reported a revenue of 248 million yuan for 2024, marking a year-on-year growth of 21.16% [1] - The establishment of the "Regenerative Medicine Center" signifies a strategic expansion into cell therapy, potentially becoming a new growth highlight for the company [1] - The completion of the first phase of the Lingang Industrial Base enhances the company's production capabilities, positioning it as a leading provider of one-stop services for cell and gene therapy product development [1] Financial Performance - The company achieved CDMO sales revenue of 135 million yuan, an increase of 26.12% compared to the previous year [2] - New CDMO business orders exceeded 270 million yuan during the year, indicating strong demand and order progress [2] - The company assisted clients in obtaining 12 IND approvals within the reporting period, contributing to a total of 44 IND approvals to date [2] Strategic Initiatives - The company initiated a share repurchase plan in 2025, having repurchased approximately 18.73 million shares, accounting for 2.8853% of total shares, with an average price of 5.34 yuan per share [2] - Part of the repurchased shares is intended for equity incentives, aiming to align the interests of the core team with the company's long-term development [2] - The company continues to leverage its diverse technical capabilities across various cell therapy fields, including oncolytic viruses, AAV gene therapy, CAR-T/NK, and stem cells [2]

Core Viewpoint - The Shanghai municipal government emphasizes the need for comprehensive regulation in the healthcare sector, leveraging advanced technologies to ensure the protection of public rights and support innovation in new healthcare models [1] Group 1: Regulatory Framework - The meeting highlighted the emergence of new healthcare services and models, necessitating the improvement of the comprehensive regulatory system in the healthcare industry [1] - A shift from post-event handling to full-process regulation is proposed, utilizing technologies such as artificial intelligence, big data, and blockchain for in-depth oversight [1] Group 2: Innovation and Development - The government aims to adopt a prudent and inclusive approach to foster innovative development in healthcare, particularly in areas like medical AI and cell therapy [1] - Support and regulation for new business models such as internet healthcare and international medical tourism are emphasized to better meet the high-quality health demands of the public [1]